Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
A triple-action Formula for comprehensive respiratory relief
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
The company has been awarded a contract for the supply of essential pharmaceutical formulations to government health institutions across Rajasthan
The NovaSeq X system features Illumina's cutting-edge XLEAP-SBS chemistry, offering unmatched throughput, accuracy, and sustainability
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
Subscribe To Our Newsletter & Stay Updated
